'I Thought It Was My Diabetes': An Acute Presentation of Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder (NMOSD) is an immune-mediated neuroinflammatory disease of the central nervous system. Patients typically present with sensory deficits, weakness, and incontinence. This is a case of a 43-year-old female with diabetes mellitus admitted for acute onset leg weakness and stool incontinence. Spinal MRI imaging revealed transverse myelitis, and her lab work was significant for an anti-aquaporin 4 (AQP4) antibody titer of 1:2,560. Initial treatment consisted of a high-dose steroid taper and plasmapheresis. This unique case illustrates the importance in recognizing delayed presentations of rare neuroinflammatory conditions previously assumed to be a sequela of diabetic neuropathy.

Meta-Analysis Assessing Efficacy and Safety of Vitamin K Antagonists Versus Direct Oral Anticoagulants for Atrial Fibrillation After Transcatheter Aortic Valve Implantation

Patients who underwent transcatheter aortic valve implantation (TAVI) with concomitant atrial fibrillation (AF) are at a higher risk for thromboembolic and bleeding events. The optimal antithrombotic strategy for patients with AF after TAVI remains unclear. We sought to determine the comparative efficacy and safety of direct oral anticoagulants (DOAC) versus oral vitamin K antagonists (VKAs) in these patients. Electronic databases such as PubMed, Cochrane, and Embase databases were searched till January 31, 2023, for relevant studies evaluating clinical outcomes of VKA versus DOAC in patients with AF after TAVI. Outcomes assessed were (1) all-cause mortality, (2) stroke, (3) major/life-threatening bleeding, and (4) any bleeding. Hazard ratios (HRs) were pooled in meta-analysis using random effect model. Nine studies (2 randomized and 7 observational) were included in systematic review, and 8 studies with 25,769 patients were eligible to be included in the meta-analysis. The mean age of the patients was 82.1 years, and 48.3% were male. Pooled analysis using random-effects model showed no statistically significant difference in all-cause mortality (HR 0.91, 95% confidence interval [CI] 0.76 to 1.10, p = 0.33), stroke (HR 0.96, 95% CI 0.80 to 1.16, p = 0.70), and major/life-threatening bleeding (HR 1.05, 95% CI 0.82 to 1.35, p = 0.70) in patients that received DOAC compared with oral VKA. Risk of any bleeding was lower in the DOAC group compared with oral VKA (HR 0.83, 95% CI 0.76 to 0.91, p = 0.0001). In patients with AF, DOACs appear to be a safe alternative oral anticoagulation strategy to oral VKA after TAVI. Further randomized studies are required to confirm the role of DOACs in those patients.

Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials

INTRODUCTION

The American Heart Association/American College of Cardiology guidelines on dual antiplatelet therapy (DAPT) recommend at least 12 months of a P2Y12 inhibitor and low dose aspirin in patients with an acute coronary syndrome (ACS) treated with a stent. Since that recommendation, several randomized controlled trials (RCTs) have studied an abbreviated duration of DAPT in ACS. Therefore, we sought to perform a meta-analysis of RCTs comparing 3- versus 12-month DAPT in patients presenting with ACS undergoing percutaneous coronary intervention (PCI).

METHODS

PubMed, Embase, and Cochrane Central databases were searched until July 31, 2022, for RCTs comparing 3- versus 12-month DAPT in patients with ACS undergoing PCI. Outcomes assessed were major adverse cardiovascular events (MACE), cardiovascular mortality, all-cause mortality, myocardial infarction (MI), stent thrombosis (ST) and bleeding. A random-effects model was used to calculate pooled relative risk (RR) and 95% confidence intervals (CI).

RESULTS

We included 5 trials comprising 16,781 patients with an ACS that underwent PCI. There was no significant difference in MACE (RR: 0.92; 95% CI: 0.76-1.11), cardiovascular mortality (RR: 1.26; 95% CI: 0.38-4.17), or all-cause mortality (RR: 0.92; 95% CI: 0.48-1.77) between the 2 groups. In addition, there was no difference in rates of MI (RR: 0.98; 95% CI: 0.74-1.30), or ST (RR: 1.30; 95% CI: 0.55-3.05) between 3- and 12-month DAPT. However, compared with 12-month DAPT, 3-month DAPT significantly reduced risk of major bleeding (RR: 0.53; 95% CI: 0.43-0.64).

CONCLUSIONS

In patients with ACS undergoing PCI, 3-month DAPT reduced risk of bleeding without evidence of harm.

Readmission Risk after COVID-19 Hospitalization: A Moderation Analysis by Vital Signs

Hospital admissions for coronavirus disease 2019 (COVID-19) are a common occurrence during periods of widespread viral transmission as are 30-day readmissions after COVID-19 hospitalization. This article provides an analysis of risk factors for readmission after COVID-19 hospitalization, in particular, vital signs upon discharge and their predictive value. In addition, this article evaluates whether the stabilization of vital signs within 24 hours of discharge can reduce readmission risk attributable to less modifiable primary factors such as underlying pulmonary and cardiac disease. The authors aim to aid the practicing clinician by providing an approach to safely risk stratify hospitalized COVID-19 patients who may be ready for discharge from the hospital.

Objective

Readmission to the hospital after hospitalization with coronavirus disease 2019 (COVID-19) is associated with significant morbidity and mortality. Hospital clinicians may identify the presence of a patient’s comorbid conditions, overall severity of illness, and clinical status at discharge as risk factors for readmission. Objective data are lacking to support reliance on these factors for discharge decision making. The objective of our study was to examine risk factors for readmission to the hospital after COVID-19 hospitalization and the impact of vital sign abnormalities, within 24 hours of discharge, on readmission rates.

Methods

In total, 2557 COVID-19-related hospital admissions within the Lifespan Health System, a large multicenter health system (Rhode Island), of 2230 unique patients aged 18 years and older, occurring from April 1, 2020 to December 31, 2020 were analyzed. Risk factors associated with readmission within 30 days were identified and analyzed using Cox regression. A moderation analysis by vital signs at discharge on the risk of readmission was performed.

Results

Clinical factors associated with readmissions included existing cardiovascular conditions (risk ratio 2.32, 95% confidence interval [CI] 1.10–4.90) and pulmonary disease (risk ratio 3.25, 95% CI 1.62–6.52). The absence of abnormal vital signs within 24 hours of discharge was associated with decreased 30-day readmission rates (risk ratio 0.70, 95% CI 0.52–0.94). Elevated C-reactive protein and d-dimer values and in-hospital complications including stroke, myocardial infarction, acute renal failure, and gastrointestinal bleeding were not associated with an increased risk of readmission. In moderation analysis, the presence of normal vital signs within 24 hours of discharge was associated with decreased readmission risk in patients who had primary risk factors for readmission including pulmonary disease (risk ratio 0.80, 95% CI 0.65–0.99), psychiatric disorders, and substance use (risk ratio 0.70, 95% CI 0.52–0.94).

Conclusions

Comorbid conditions, including pulmonary and cardiovascular disease, are associated with readmission risk after COVID-19 hospitalization. The normalization of vital signs within 24 hours of discharge during COVID-19 hospitalization may be an indicator of readiness for discharge and may mitigate some readmission risk conferred by comorbid conditions.

Disease Severity in Vaccinated Adults Hospitalized with Breakthrough COVID-19

Background: Vaccination against SARS-CoV-2 is widely used and confers protection against morbidity and mortality in COVID-19. Little is known about disease severity and outcomes in fully vaccinated patients during hospitalization for COVID-19. Aim: To determine whether vaccination status and time from vaccination-to-hospitalization impacted disease severity in patients admitted with COVID-19. Methods: A multicenter retrospective cohort study was conducted on hospitalized adults with COVID-19 between January 1 and September 8, 2021, in Rhode Island, USA. Vaccination status and markers of disease severity, including C-reactive protein, D-Dimer values, and supplemental oxygen use during hospitalization, were obtained. Results: Two thousand three hundred forty-four patients were included. For every vaccinated patient, three unvaccinated patients were matched for a total of 424 patients in the analytic sample. Vaccinated patients had lower peak C-reactive protein (beta = -39.10, 95% CI [-79.10, -0. 65]) and supplemental oxygen requirements (beta = -38.14, 95% CI [-61.62, -9.91]) compared to unvaccinated patients. Patients who had a greater discrepancy between date of vaccination and admission had higher C-reactive protein (beta = 0.37, 95% CI [0.02, 0.71]) and supplemental oxygen requirements (beta = 0.44, 95% CI [0.15, 0.75]. Conclusion: Vaccination against SARS-CoV-2 was associated with a protective effect on disease severity during hospitalization for breakthrough COVID-19. Time elapsed since vaccination was associated with indicators of greater disease severity suggestive of waning protection over time.

Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials

BACKGROUND

To date, only dexamethasone and tocilizumab have been shown to reduce mortality in patients with COVID-19. Baricitinib is a Janus kinase 1/2 inhibitor with known anti-inflammatory and anti-viral properties. We performed a meta-analysis of RCTs assessing the role of baricitinib in hospitalised patients with COVID-19.

METHODS

Electronic databases such as MEDLINE, EMBASE, and Cochrane Central were searched up until March 31, 2022, for RCTs evaluating the efficacy of baricitinib in hospitalised patients with COVID-19. The outcomes assessed were 28-day mortality, progression to invasive mechanical ventilation (IMV) or ECMO, progression to respiratory failure needing positive pressure ventilation, IMV or death, duration of hospitalisation and time to discharge. The meta-analysis was registered in the PROSPERO database (CRD42022314579).

FINDINGS

Four studies (with 10,815 patients) were included in the analysis. Pooled analysis using random-effects model showed a statistically significant reduction in 28-day mortality (OR 0.69, 95% CI 0.50-0.94; p=0.04, I²=65%) and composite outcome of progression to severe disease needing positive pressure ventilation, IMV or death (OR 0.89, 95% CI 0.80-0.99, p= 0.03, I²=0%). There was a favorable trend towards reduced progression to IMV or ECMO (OR 0.76, 95% CI 0.58-1.01; p=0.06, I²=49%) in the baricitinib arm compared to standard therapy, even though it was not statistically significant. Statistical significance was achieved for all outcomes with fixed-effects model analysis.

INTERPRETATION

In hospitalised patients with COVID-19, baricitinib was associated with reduced 28-day mortality although there was not a statistically significant reduction in progression to IMV or ECMO. Baricitinib used in conjunction with standard of care treatments is associated with improved mortality in hospitalised patients with COVID-19 disease.

FUNDING

None.

Severe multisystem inflammatory syndrome in a vaccinated adult with COVID-19

The ability of SARS-CoV-2 to trigger hyperinflammatory response in children and adults is increasingly recognised. However, the detailed features that distinguish severe COVID-19-associated hyperinflammation from multisystem inflammatory syndrome in adults (MIS-A) is not yet known. We describe a young, vaccinated patient with no prior SARS-CoV-2 exposure who developed COVID-19 and MIS-A. We also provide a review of the current literature on MIS-A and COVID-19-associated hyperinflammation.

The Treatment of COVID-19 Purgatory Syndrome With Tocilizumab and Steroids

Hyperinflammation is a key component of severe coronavirus disease 2019 (COVID-19) and is associated with poor outcomes. It is imperative to distinguish severe COVID-19 from hyperinflammatory syndromes such as multisystem inflammatory syndrome (MIS) and hemophagocytic lymphohistiocytosis. There is a subset of post-COVID-19 patients who present with some symptoms characteristic of MIS in adults (MIS-A) yet do not meet all the criteria for a diagnosis. We describe the unique case of a patient with this kind of presentation who clinically improved following tocilizumab and corticosteroid usage.

Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19

Background

Since the beginning of COVID-19 pandemic, there has been a widespread use of remdesivir in adults and children. There is little known information about remdesivir's role in reducing 30-day readmissions after hospitalization with COVID-19. This study aimed to determine whether treatment with remdesivir was associated with reduced risk of 30-day readmission after index hospitalization with COVID-19.

Methods

The study was a multi-center cohort study in Rhode Island, USA. Patients included all adults that were discharged after hospital treatment for COVID-19 between April 1^st and December 31^st, 2020. The main study outcomes were length of hospital stay, 30-day readmission, and post-discharge 30 days mortality.

Results

A total of 2,062 patients (2,279 hospitalizations) were included in the analytic sample. Patients were less likely to be readmitted within 30 days if they received remdesivir relative to not receiving remdesivir; associations were strongest for those with mild disease (RR: 0.31; 95% CI: 0.13,0.75). Remdesivir treatment was associated with reduction in all-cause mortality (HR: 0.65; 95% CI: 0.49,0.85) and an increase in length of stay (estimated average increase of 3.27 days; 95% CI: 2.11,4.44). Limitation: Unmeasured factors such as time-to-treatment and severity of disease prior to initiation of remdesivir.

Conclusions

Remdesivir may be an effective strategy for reducing progression to severe COVID-19 disease and limiting morbidity associated with readmission to hospital. Larger prospective studies are justified to study the role of remdesivir in mild or early COVID-19 with high risk of disease progression and readmission to hospital within 30 days.

Acute Nephrotic Syndrome and Otosyphilis

Syphilis, also known as the "the great masquerader," is a re-emerging infectious disease in the Western world, and may present with various signs and symptoms, making it difficult to distinguish from other diseases. Nephrotic syndrome due to syphilis has been rarely reported in modern times. Here, we describe a young male with acute hearing loss and peripheral edema, found to have acute nephrotic syndrome in the setting of otosyphilis. Given increasing incidence of syphilis, physicians must remain alert to syphilis as a possible cause of nephrotic syndrome.

Heart failure in COVID-19 patients: Critical care experience

Patients with heart failure (HF) may be at a higher risk of coronavirus disease 2019 (COVID-19) infection and may have a worse outcome due to their comorbid conditions and advanced age. In this narrative review, we aim to study the interaction between COVID-19 and HF from a critical care perspective. We performed a systematic search for studies that reported HF and critical care-related outcomes in COVID-19 patients in the PubMed and Medline databases. From a total of 1050 papers, we identified 26 that satisfied the eligibility criteria for our review. Data such as patient demographics, HF, intensive care unit (ICU) admission, management, and outcome were extracted from these studies and analyzed. We reported outcomes in heart-transplant patients with COVID-19 separately. In hospitalized patients with COVID-19, the prevalence of HF varied between 4% and 21%. The requirement for ICU admission was between 8% and 33%. HF patients with COVID-19 had an overall mortality rate between 20% and 40%. We identified that HF is an independent predictor of mortality in hospitalized COVID-19 patients, and patients with HF were more likely to require ventilation, ICU admission and develop complications. Patients with HF with reduced ejection fraction did worse than those with HF with midrange ejection fraction, and HF with preserved ejection fraction. COVID-19 patients with HF should be identified early and managed aggressively in an attempt to improve outcomes in this cohort of patients.

Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease

BACKGROUND

Since the beginning of corona virus disease 2019 (COVID-19) pandemic, there has been a widespread use of remdesivir in adults and children. There is little known information about its outcomes in patients with end stage renal disease who are on dialysis.

AIM

To assess the clinical outcomes with use of remdesivir in adult patients with end stage kidney failure on hemodialysis.

METHODS

A retrospective, multicenter study was conducted on patients with end stage renal disease on hemodialysis that were discharged after treatment for COVID-19 between April 1, 2020 and December 31, 2020. Primary endpoints were oxygen requirements, time to mortality and escalation of care needing mechanical ventilation.

RESULTS

A total of 45 patients were included in the study. Twenty patients received remdesivir, and 25 patients did not receive remdesivir. Most patients were caucasian, females with diabetes mellitus and hypertension being the commonest comorbidities. There was a trend towards reduced oxygen requirement (beta = -25.93, X² (1) = 6.65, P = 0.0099, probability of requiring mechanical ventilation (beta = -28.52, X² (1) = 22.98, P < 0.0001) and mortality (beta = -5.03, X² (1) = 7.41, P = 0.0065) in patients that received remdesivir compared to the control group.

CONCLUSION

Larger studies are justified to study the effects of remdesivir in this high-risk population with end stage kidney disease on dialysis.

A Tale of Two Ps: Panniculitis Secondary to Acute Pancreatitis

Pancreatic panniculitis (PP) is a rare variant of panniculitis that affects patients with pancreatic disorders, most commonly pancreatic malignancy or acute/chronic pancreatitis. Patients often present with painful, erythematous nodules on their lower extremities that may undergo spontaneous ulceration and necrosis. Treatment is largely supportive and should address the underlying pancreatic disease.

Cryptic Presentation of Disseminated Cryptococcosis

Cryptococcosis is a global invasive mycosis, commonly encountered in patients with HIV/AIDS with low CD4 counts, diabetics, organ and stem-cell transplant recipients, malignancies, and other patients with immunosuppression. The presentation depends on which organ is usually involved although multi-organ involvement may be present. Here, we describe a young female with an enlarging flank mass, found to have disseminated cryptococcosis in the setting of immunosuppression.

A review of the presentation and outcome of left ventricular thrombus in coronavirus disease 2019 infection

BACKGROUND

Cardiovascular complications of the coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), have been documented both in the acute phase and in convalescence. One such complication is the formation of the left ventricular (LV) thrombus. There is a lack of clarity regarding the incidence, risk factors, and management of this complication.

AIM

The aim of the study is to identify the clinical presentation, risk factors and outcome of COVID-19 patients with left ventricular thrombus (LVT).

METHODS

A literature search was conducted to identify all case reports of COVID-19 with LVT in PubMed/Medline, Embase, Web of Science, and Google Scholar.

RESULTS

Among the 65 patients identified, 60 had LVT, either at admission, or during the acute phase of the illness. Six patients with mild symptoms during the acute phase of viral illness had only the COVID-19 antibody test positivity at the time LV thrombus was detected. Few of the patients (23.1%) had no comorbidities. The mean age of the patients was 52.8 years, and the youngest patient was 4 years old. This suggests that LVT formation can occur in young COVID-19 patients with no co-morbid conditions. Most of the patients (69.2%) had more than one site of thrombosis. A mortality rate of 23.1% was observed in our review, and ST-elevation myocardial infarction (STEMI) was diagnosed in 33.3% of those who died.

CONCLUSIONS

A high degree of suspicion for LVT must be maintained in patients with known cardiac disease and those with new-onset arterial or venous thromboembolism, and such patients may benefit from a screening echocardiography at admission.

RELEVANCE FOR PATIENTS

The patients with preexisting cardiovascular disease must take added precautions to prevent acquiring COVID-19 infection as there is a higher risk of developing LV thrombus. In patients who develop LVT in COVID-19, mortality rate is higher.

An Unusual Presentation of Kikuchi-Fujimoto Disease with Recurrent Fever and Syncope

Kikuchi-Fujimoto (KF) disease, also known as necrotizing histiocytic lymphadenopathy, is a rare, benign disorder of the lymph nodes of young adults, predominantly young females. The exact cause of KF disease is unknown. Here, we report a young female with recurrent fever and syncopal episodes diagnosed with KF disease on lymph node biopsy.

Complete heart block associated with Remdesivir in COVID-19: a case report

Background

Since the pandemic began in 2020, Remdesivir has been widely used for the treatment of coronavirus disease-2019 (COVID-19). Here, we describe a case of a patient with COVID-19 who developed transient complete atrioventricular (AV) block and bradycardia after initiating treatment with Remdesivir.

Case summary

A 72-year-old male with a history of atrial fibrillation and lung cancer was hospitalized for COVID-19. Electrocardiogram (ECG) on admission demonstrated atrial fibrillation and right bundle branch block. He was started on a course of Dexamethasone and Remdesivir. Within 24 h of starting Remdesivir, he was noted to be in atrial fibrillation with ventricular rates between 30 and 40 b.p.m. On Day 5 of Remdesivir therapy, ECG demonstrated complete AV block. Having completed the Remdesivir regimen, during the next 48 h, he was closely monitored, and the AV block resolved spontaneously. As he remained asymptomatic and had an adequate chronotropic response with activity, pacemaker implantation was not recommended.

Discussion

Despite the widespread use of Remdesivir, there is little known information about its cardiac toxicity. Daily ECGs and close cardiac surveillance of patients who develop severe bradycardia or AV block are essential. Discontinuation of the medication usually results in the resolution of these cardiac disturbances.

Presentations and Outcomes of Severe Cardiac Complications in COVID-19: Rhode Island Experience

Forty-one (41) patients admitted to Rhode Island hospitals with COVID-19 from April to November 2020 were identified to have severe cardiac complications. Clinical presentations of cardiovascular system toxicity in COVID-19 included myocarditis, pericarditis, cardiomyopathy, ACS and cardiac arrhythmia. Clinical features, hospital outcomes and post-discharge outcomes were characterized. Acute myocarditis (46.3%) and cardiomyopathy (29.3%) were the most common findings followed by cardiac arrhythmia, acute coronary syndrome, and pericardial disease. Pulmonary involvement of COVID-19 was absent in 41.5% of patients. Comorbid cardiovascular conditions were absent in 29.3% of patients. Severe cardiac complications in COVID-19 were associated with an in-hospital mortality rate of 61%. Among survivors with COVID-19-related cardiomyopathy, only 20% demonstrated recovery of LV function on follow-up echocardiography done within 12 weeks after initial diagnosis. Identification, diagnosis and management of severe cardiac complications in COVID-19 are discussed.

Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials

Background

To date, only dexamethasone has been shown to reduce mortality in coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the treatment guidelines for hospitalized COVID-19 patients, but data remain conflicting.

Study Design and Methods

Electronic databases such as MEDLINE, EMBASE, and Cochrane central were searched from March 1, 2020, until March 10, 2021, for randomized controlled trials evaluating the efficacy of tocilizumab in hospitalized COVID-19 patients. The outcomes assessed were all-cause mortality, mechanical ventilation, and time to discharge.

Results

Nine studies (with 6490 patients) were included in the analysis. In total, 3358 patients received tocilizumab, and 3132 received standard care/placebo. Pooled analysis showed a significantly decreased risk of all-cause mortality (RR 0.89, 95% CI 0.80–0.98, p = 0.02) and progression to mechanical ventilation (RR 0.80, 95% CI 0.71–0.89, p < 0.0001) in the tocilizumab arm compared to standard therapy or placebo. In addition, there was a trend towards improved median time to hospital discharge (RR 1.28, 95% CI 1.12–1.45, p = 0.0002).

Conclusions

Tocilizumab therapy improves outcomes of mortality and need for mechanical ventilation, in hospitalized patients with COVID-19 infection compared with standard therapy or placebo. Our findings suggest the efficacy of tocilizumab therapy in hospitalized COVID-19 patients and strengthen the concept that tocilizumab is a promising therapeutic intervention to improve mortality and morbidity in COVID-19 patients.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00408-021-00451-9.

Chronic Hypotension Due to Thrombosis of an Inferior Vena Cava Filter

Inferior vena cava filters (IVCF) are associated with many long-term complications. Often, these complications manifest as acute events, such as shock. However, we report a case of a patient who presented with chronic hypotension and dizziness due to a thrombosed IVCF filter.

Molecular epidemiology of HBV among HIV infected individuals in Chennai, south India

Hepatitis B is a major co-infection among people with HIV (PWHIV) worldwide. There is a paucity of data on HBV genetic diversity in India, which would be useful for targeted preventive and management interventions. To characterize the distribution of HBV genotypes and sub-genotypes, samples of 180 HIV-HBV co-infected individuals from a study previously conducted to estimate the prevalence of HBV co-infection were analyzed. Nested PCR using type-specific primers was used to identify the various HBV genotypes. Partial HBV S sequences were generated for a subset of samples using Sanger sequencing. Mutation analysis was done using the online HBVseq program. PCR based genotyping documented D (69.4 %) and A (5.6 %) to be the major genotypes in the study population. Infection with multiple genotypes was observed in 25 % co-infected individuals. D2, D5, A2, and A1 were the sub-genotypes detected. Mutations 184K and 173L were identified. HBV genotypes/ sub-genotypes play a pivotal role in the clinical outcome of chronic hepatitis B (CHB). Therefore, monitoring of CHB cases is needed to track disease progression, including early detection of hepatocellular carcinoma.

Endocrinological abnormalities and Takotsubo cardiomyopathy

Dear Editor, We read with much excitement in the article "Takotsubo syndrome and pheochromocytoma: an insidious combination" published by Maffé et al. in your esteemed journal...

COVID-19-induced granulomatosis with polyangiitis

COVID-19 and granulomatosis with polyangiitis share many clinical and radiological features, making it challenging for clinicians to distinguish between the two. In this case report, we describe a patient who was diagnosed with COVID-19 in October 2020. One month later, she presented with persistent fatigue, shortness of breath and anaemia with worsening renal functions, found to have elevated antineutrophil cytoplasmic antibodies and antiproteinase 3 antibodies, and diagnosed with granulomatosis with polyangiitis.

Iatrogenic Pneumothorax and Pneumomediastinum in a Patient with COVID-19

Co-occurrence of pneumothorax and pneumomediastinum is rare in COVID-19 patients. Positive airway pressure therapy used to improve oxygenation may sometimes worsen clinical outcomes in some patients with severe COVID-19 pneumonia. In this case report, we describe an individual who was diagnosed with COVID-19 and developed bilateral pneumothorax and pneumomediastinum after initiating non-invasive positive airway pressure therapy.

Severe, Symptomatic Reinfection in a Patient with COVID-19

To date, there have only been a few reports of reinfections in COVID-19 patients. The possibility of being reinfected with COVID-19 is poorly understood. In this case report, we describe an individual who was initially diagnosed in April 2020 with COVID-19. Seven months later, he presented again to the hospital with shortness of breath and was found to have COVID-19 reinfection. We also summarize a list of all known cases of COVID-19 reinfection at this time.

Advanced development of dairy farm waste-based biocarbon-reinforced unsymmetrical structured bio-phenolic polybenzoxazine composites

In the present work, an attempt has been made to develop cow manure carbon-reinforced hybrid biophenol-based benzoxazine composites for antifouling coating applications. Bio-based benzoxazine with unsymmetrical molecular structure was synthesized using the mixture of a combination of cardanol and eugenol with diaminodiphenyl methane and paraformaldehyde, and the hybrid-benzoxazine obtained was characterized using different analytical techniques, viz., Fourier transform infrared, nuclear magnetic resonance and MALDI mass. Bio-based benzoxazine was further reinforced with varying weight percentages (1, 3 and 5 wt%) of biocarbon derived from cow manure to obtain hybrid composite coatings. The hybrid benzoxazine matrix and composites were studied for their thermal behaviour, contact angle (CA), morphology, corrosion-resistant behaviour and antifouling character to utilize them as coatings materials for different industrial applications. Results obtained from different studies inferred that the biocarbon-reinforced composites possess an enhanced value of glass transition temperature (249°C), high char yield (38.4%), improved CA (105.6°), higher efficiency of corrosion protection against mild steel surface (98%) and improved antimicrobial activity.

Short-Term Dexamethasone in Sars-CoV-2 Patients

BACKGROUND

Dexamethasone, a synthetic glucocorticoid, has anti-inflammatory and immunosuppressive properties. There is a hyperinflammatory response involved in the clinical course of patients with pneumonia due to SARS-CoV-2. To date, there has been no definite therapy for COVID-19. We reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.

METHODS

We describe a series of 21 patients who tested positive for SARS-CoV-2 and were admitted to The Miriam Hospital in Providence, RI, and were treated with a short course of dexamethasone, either alone or in addition to current investigative therapies.

RESULTS

CRP levels decreased significantly following the start of dexamethasone from mean initial levels of 129.52 to 40.73 mg/L at time of discharge. 71% percent of the patients were discharged home with a mean length of stay of 7.8 days. None of the patients had escalation of care, leading to mechanical ventilation. Two patients were transferred to inpatient hospice facilities on account of persistent hypoxemia, in line with their documented goals of care.

CONCLUSIONS

A short course of systemic corticosteroids among inpatients with SARS-CoV-2 with hypoxic respiratory failure was well tolerated, and most patients had improved outcomes. This limited case series may not offer concrete evidence towards the benefit of corticosteroids in COVID-19. However, patients' positive response to short-term corticosteroids demonstrates that they may help blunt the severity of inflammation and prevent a severe hyperinflammatory phase, in turn reducing the length of stay, ICU admissions, and healthcare costs.

Acute Vision Loss in a Patient with COVID-19

To date, there have been reports of neurologic manifestations in COVID-19 patients including ischemic strokes, Guillain-Barre Syndrome and anosmia. In this case report, we describe a patient who presented with dysosmia, dysgeusia, along with monocular peripheral vision loss after being diagnosed with COVID-19.

Development of Prosopis juliflora carbon-reinforced PET bottle waste-based epoxy-blended bio-phenolic benzoxazine composites for advanced applications

An attempt has been made in the present work to develop hybrid blended composites using epoxy resin (PETEP) derived from waste polyethylene terephthalate (PET) bottles and bio-phenolic (cardanol)-based benzoxazine (CBz) reinforced with functionalized bio-carbon (f-PJC) obtained from Prosopis juliflora (PJ) for high performance applications. The molecular structure, thermal properties, thermo-mechanical behaviour, morphology, surface properties, and corrosion resistance of the composites were studied by different analytical methods, and the obtained results are reported. Dynamic mechanical properties such as the storage modulus (2.591 GPa), loss modulus (1.299 GPa) and cross-linking density (5.1 × 10⁷ J mol⁻¹ K⁻¹) were improved in the case of the 5 wt% f-PJC/PETEP–CBz composite compared to those of the PETEP–CBz blended matrix and the f-PJC/PETEP–CBz composites with other weight percentages. Among the studied bio-carbon-reinforced hybrid composites with different weight percentages, the 5 wt% f-PJC/PETEP–CBz composite shows a higher value of char yield (38.37%), with an enhanced glass transition temperature of 285 °C and an improved water contact angle of 111.3°. Results obtained from corrosion studies infer that these hybrid composites exhibit improved corrosion resistance behaviour and effectively protect the surface of mild steel specimens from corrosion. It is concluded that the present work can be considered as an effective method for utilizing waste products and sustainable bio-materials for the development of high performance value-added hybrid composites for thermal and corrosion protection applications.

Schematic representation of development of functionalised Prosopis juliflora carbon (f-PJC) reinforced PET-epoxy resin (PETEP) blended bio-phenolic (cardanol) based benzoxazine (CBz) hybrid composites for high performance applications.

Column specific fixation for complex tibial plateau fractures - Midterm prospective study in South - Indian population

BACKGROUND

Tibial plateau fractures involving two or more columns were routinely assessed by two-dimensional radiography in the past. This often misled surgeons and attention was given only to the medial and lateral column without consideration of the posterior column, especially the postero-medial corner. Luo in 2010 introduced the new three-column classification system based on multiplanar computed tomography images. This study was conducted to assess the outcome after internal fixation of tibial plateau fractures involving two or more columns in our centre based on the column specific approach.

MATERIALS AND METHODS

This was a prospective study conducted at our institute, between 2011 and 2016. Total of 183 patients with tibial plateau fractures involving two or more columns were admitted during this study period of which 123 patients were satisfied our inclusion criteria. 8 patients were lost to follow up. Hence 115 patients with tibial plateau fractures involving two or more columns were classified based on the new three column classification system. Dual column fixation (Anterolateral +Anteromedial) was done in 76 patients, (Anterolateral+Posteromedial) fixation in 25 patients and triple column fixation (Anterolateral + Anteromedial + Posteromedial) in 14 patients. Post operatively patients were assessed by Modified Rasmussen functional and radiological scoring system.

RESULTS

Based on Modified Rasmussen functional scoring system, 73 patients (63.5%) had excellent results, 37 patients (32.2%) had good results and 5 patients (4.3%) had fair results. Based on Modified Rasmussen radiological scoring system, 71 patients (61.7%) had excellent results, 38 patients (33.1%) had good results, 6 patients (5.2%) had fair results. 3 patients had deep infections.

CONCLUSION

Based on our study, we like to conclude that we had good outcomes utilizing this modern column specific approach to the treatment of these two or more column tibial plateau fracture injuries, which includes assessment of three columns.

Evaluation of thermo-mechanical, dielectric and corrosion resistant properties of cardanol benzoxazine-epoxy based hybrid composites: A very low temperature curing pre-polymer for high performance paint related applications

In the present work, the hybrid siloxane-based cardanol-benzoxazine-epoxy (1:1 ratio) matrix (SBCBz-EP) capable of curing at substantially low temperature when compared with that of conventional benzoxazines was prepared and characterized. The matrix SBCBz-EP was reinforced with varying weight percentages (1, 3 and 5 wt%) of hydroxyl-terminated cyclotriphosphazene (HTCP) and the resulting hybrid composites were characterized by modern analytical methods, which can be used for paint-related applications due to their low-temperature curing behaviour. Data obtained from differential scanning calorimeter analysis infer that the glass transition temperature of the hybrid matrix (SBCBz-EP) and HTCP reinforced with 1, 3 and 5 wt% composites was 73°C, 75°C, 82°C, and 88°C, respectively. The polymerization temperature obtained for SBCBz-EP matrix and HTCP-reinforced hybrid composites was considerably lower than that of conventional benzoxazines. The present hybridization approach of benzoxazine and epoxy paves an avenue to alleviate the deficient characteristics of both industrially valuable resins namely high curing temperature and brittle behaviour of benzoxazines and also to improve thermal stability, mechanical strength and flame-retardant behaviour of epoxy resins. Data obtained from mechanical, dielectric, thermal stability and corrosion-resistant studies indicate that the properties of hybrid composites (HTCP/SBCBZ-EP) were enhanced to an appreciable extent according to the wt% of HTCP and it can be suggested that these hybrid composite materials can be used in the form of adhesives, sealants, encapsulants and water-resistant coatings for high performance industrial applications.

Bubbles in the Brain: A Rare Complication Following Transthoracic Echocardiography

With nearly 700,000 cases every year, ischemic stroke represents the third leading cause of death in the United States.1,2 Nearly thirty percent of all ischemic strokes are due to embolism.3 A standard component of every stroke work-up at most institutions, echocardiography is vital not only for diagnosis but also for prevention and treatment of cardiac sources of embolism. Visualization of right-to-left shunting is often contrast-enhanced with micro bubbles created by mixing saline with air, a so-called "bubble study." We present a case of an 89-year-old woman who suffered cerebral air embolism and massive infarction following a routine bubble Transthoracic Echocardiogram.

Transfibular ankle arthrodesis: A novel method for ankle fusion - A short term retrospective study

BACKGROUND

Ankle arthrodesis has long been the traditional operative treatment for posttraumatic arthritis, rheumatoid arthritis, infection, neuromuscular conditions, and salvage of failed ankle arthroplasty. It remains the treatment of choice for patients in whom heavy and prolonged activity is anticipated. We present our short term followup study of functional outcome of patients who underwent transfibular ankle arthrodesis for arthritis of ankle due to various indications.

MATERIALS AND METHODS

29 transfibular ankle arthrodesis in 29 patients performed between April 2009 and April 2014 were included in this study. The mean age was 50 years (range 22-75 years). The outcome analysis with a minimum of 1-year postoperative followup were included. All the patients were assessed with the American Orthopaedic Foot and Ankle Society (AOFAS) Hindfoot scale.

RESULTS

All cases of ankle fusions (100%) progressed to solid union in a mean postoperative duration of 3.8 months (range 3-6 months). All patients had sound arthrodesis. The mean followup period was 32.52 months (standard deviation ± 10.34). The mean AOFAS score was 74 (pain score = 32, functional score = 42). We found that twenty patients (68.96%) out of 29, had excellent results, 7 (24.13%) had good, and 2 (6.89%) showed fair results.

CONCLUSION

Transfibular ankle arthrodesis is a simple and effective procedure for ankle arthritis. It achieves a high rate of union and good functional outcome on midterm followup.

Bio-based silica-reinforced caprolactam-toughened epoxy nanocomposites

In this work, industrially valuable and versatile nylon 6 precursor material caprolactam has been used as a toughener for diglycidyl ether of bisphenol A epoxy resin (caprolactam epoxy (CPE)) along with glycidyl-functionalized bio silica (GRS) derived from rice husk, which was used as a reinforcement to obtain hybrid nanocomposites with improved properties. Caprolactam (20 wt%) and epoxy (80 wt%) have been reinforced with varying weight percentages (0.5, 1.0 and 1.5 wt%) of GRS cured with diaminodiphenylmethane and characterized using different analytical techniques. Data obtained from mechanical studies indicate that the value of tensile strength, flexural strength and impact strength of 1.5 wt% GRS-reinforced caprolactam-toughened epoxy blend composites were enhanced to 135, 77 and 162%, respectively, compared with those of neat epoxy matrix. Similarly, the values of glass transition temperature and char yield were enhanced to 21 and 22%, respectively, whilst retaining inherent surface and insulating behaviour. Data from morphological studies infer the homogenous and uniform distribution of GRS in the CPE hybrid nanocomposites. From the data obtained from different studies, it is suggested that the hybrid composite materials developed in this work have potential use as coatings, adhesives, sealants, matrices and composites for different industrial and engineering applications in the place of conventional epoxy composites for improved performance and enhanced longevity.

Outcomes of patients with acute decompensated heart failure managed by cardiologists versus noncardiologists

Physician practice patterns in the management of hospitalized acute decompensated heart failure (ADHF) patients may vary by specialty; comparative practice patterns in ADHF management and clinical outcomes as a function of provider type have not been well reported. We studied a total of 496 patients discharged with the principal diagnosis of ADHF to analyze practice patterns among 3 provider types (cardiologists, hospitalists, and nonhospitalists). We examined outcomes of death and rehospitalization for HF and adherence to the Joint Commission HF performance core measures. Cardiologists had the highest adherence in all 4 HF core measures compared with hospitalists and nonhospitalists. At 6 months, 6.0% of the patients cared by cardiologists died compared with 10.9% and 11.4% cared by hospitalist and nonhospitalists (p = 0.12). Patients cared for by cardiologists had a significantly lower 6-month ADHF readmission rate (16.2%) compared with hospitalists (40.1%) and nonhospitalists (34.9%, p <0.001). In multivariate analysis, both hospitalist and nonhospitalist provider types were an independent predictor for 6-month ADHF-related readmission (hospitalists vs cardiologists, hazard ratioadjusted 3.01; 95% confidence interval 1.84 to 4.89, p <0.001; and nonhospitalists vs cardiologists, hazard ratioadjusted 2.07; 95% confidence interval 1.24 to 3.46, p = 0.005). In conclusion, cardiologist-delivered ADHF care is associated with greater adherence to HF core measures and with significantly lower rates of adverse outcome compared with noncardiologists.

Mullite-reinforced caprolactam-toughened DGEBA epoxy nanocomposites

This work describes the development of different weight percentages of glycidyl functionalized mullite-reinforced caprolactam-toughened epoxy (MCEP) nanocomposites. The functionalization of mullite and MCEP are confirmed by Fourier transform infrared spectroscopic analysis. Further, the morphological, surface behaviour and thermal properties are studied using scanning electron microscopy, transmission electron microscopy, X-ray diffraction, atomic force microscopy, goniometer, thermogravimetric analysis and differential scanning calorimetry analysis. Surface studies show that the values of contact angle increased with increase in weight percentage of mullite and thus 1.5 wt% MCEP nanocomposites show values of higher contact angle (89.6°) and lower water absorption (0.107%) behaviour than those of the composites reinforced with lower wt% of mullite. Moreover, 1.5 wt% MCEP nanocomposites possess better impact behaviour (266.4 J m−2) than that of neat epoxy matrix. Thus the hybrid composite materials developed in this work are expected to find applications in different industrial and engineering sectors with improved performance and longevity.

Development of ricehusk ash reinforced bismaleimide toughened epoxy nanocomposites

Recent past decades have witnessed remarkable advances in composites with potential applications in biomedical devices, aerospace, textiles, civil engineering, energy, electronic engineering, and household products. Thermoset polymer composites have further enhanced and broadened the area of applications of composites. In the present work epoxy-BMI toughened-silica hybrid (RHA/DGEBA-BMI) was prepared using bismaleimide as toughener, bisphenol-A as matrix and a silica precursor derived from rice husk ash as reinforcement with glycidoxypropyltrimethoxysilane as coupling agent. Differential scanning calorimetry, electron microscopy, thermogravimetric analysis, and goniometry were used to characterize RHA/DGEBA-BMI composites developed in the present work. Tensile, impact and flexural strength, tensile and flexural modulus, hardness, dielectric properties were also studied and discussed. The hybrid nanocomposites possess the higher values of the glass transition temperature (Tg) and mechanical properties than those of neat epoxy matrix.

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

(90) Y-ibritumomab-tiuxetan ((90) YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma (FL) or marginal zone B-cell lymphoma (MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II disease and non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. (90) YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response.